BioSpace News Archive

The evolving healthcare sector has raised its demand for a multitude of equipment. One such equipment is the medical cart, which is required for moving around medical supplies in a quick manner in a room or a given premise.

Innate Pharma SA, announced that a planned futility interim analysis of the INTERLINK-1 Phase 3 study sponsored by AstraZeneca did not meet a pre-defined threshold for efficacy.

7 Hills Pharma LLC was awarded a 3-year grant worth almost $3 million from the National Institute of Allergy and Infectious Diseases to progress its work with collaborator Dr. Nisha Garg from the University of Texas Medical Branch toward the creation of the first vaccine against Chagas disease.

Oncocyte Corporation announced the appointment of John Peter Gutfreund as an independent member of its board of directors, effective July 28, 2022.

MannKind Corporation, a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, announced that its Chief Executive Officer, Michael Castagna, PharmD, and Chief Financial Officer, Steven Binder will participate in the BTIG Biotechnology Conference taking place on Monday, August 8 – Tuesday, August 9, 2022.

NanOlogy LLC, a clinical-stage interventional oncology drug company, announced that results from a clinical trial of Large Surface Area Microparticle Docetaxel in High-Risk Non-Muscle Invasive Bladder Cancer have been published in The Journal of Urology®.

Nutriband Inc. announced that it has received a Notice of Allowance from the Canadian Intellectual Property Office for its patent application, CA 2937649, entitled “Abuse and Misuse Deterrent Transdermal Systems,” that protects its AVERSA™ transdermal abuse deterrent technology.

Ra Medical Systems, Inc. announces that its audited consolidated financial statements for the fiscal year ended December 31, 2021 included in the Company’s Form 10-K filed with the Securities and Exchange Commission on March 24, 2022 and Amended Form 10-K/A filed with the SEC on July 7, 2022 contained an audit report from its independent registered public accounting firm which included a going concern emphasis of matter paragraph.

Taysha Gene Therapies, Inc. today announced its participation in panel discussions at the BTIG Biotechnology Conference on August 8th and the 2022 Wedbush PacGrow Healthcare Virtual Conference on August 10th.

ALX Oncology Holdings Inc. today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation to evorpacept, a next generation CD47 blocker, in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, for the first-line treatment of adult patients with PD-L1 positive advanced head and neck squamous cell carcinoma (“HNSCC”).